Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 61.89B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | -790.12M |
| Shares Out | 897.56M |
| EPS (ttm) | -0.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,368,271 |
| Average Volume | 8,804,645 |
| Open | 65.80 |
| Previous Close | 64.10 |
| Day's Range | 65.80 - 69.70 |
| 52-Week Range | 26.45 - 78.75 |
| Beta | 0.57 |
| RSI | 64.21 |
| Earnings Date | Mar 14, 2025 |
About Akeso
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovari... [Read more]
News
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ: BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc . ...
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...